Selective serotonin reuptake inhibitor poisoning

INTRODUCTION

The selective serotonin reuptake inhibitors (SSRIs) were introduced in the late 1980s for the treatment of depression. They are generally much safer in overdose than tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Commonly used SSRIs include fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram.

In 2011, single-substance SSRI ingestions accounted for 46,587 reported exposures to US poison centers, 90 major outcomes, and only two fatalities [1]. The incidence of SSRI ingestions has steadily increased and mirrors the increase in SSRI prescriptions [2]. Isolated SSRI ingestions generally produce mild symptoms, although SSRI intoxication can infrequently produce serotonin syndrome, seizures, CNS depression, or various cardiac abnormalities.

The toxicity and management of acute SSRI overdose will be discussed here. A summary table to facilitate emergent management of SSRI poisoning is provided (table 1). Discussions of the therapeutic use of these medications, and of serotonin syndrome, are found elsewhere. (See "Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects" and "Serotonin syndrome".)

PHARMACOLOGY AND CELLULAR TOXICOLOGY

Serotonin is produced from tryptophan, while norepinephrine and dopamine are produced from tyrosine, through similar chemical pathways in nerve terminals. These neurotransmitters are stored in cytoplasmic vesicles of presynaptic neurons and released into the synapse with nerve depolarization. Transport proteins specific for serotonin, norepinephrine, or dopamine are embedded in the presynaptic terminal cell membrane and are responsible for pumping these neurotransmitters out of the synapse and back into the cytoplasm. Once in the cytoplasm, the neurotransmitters are either repackaged into vesicles for reuse or degraded by monoamine oxidase.

Approximately 98 percent of the body's serotonin is found outside the central nervous system (CNS). Several families of serotonin receptors, with multiple subtypes, have been discovered. In the CNS, serotonergic neurons are found in the brainstem, mostly in the raphe nucleus. They have a role in regulating mood, personality, appetite, wakefulness, emesis, temperature regulation, and sexual behavior [3]. Peripherally, serotonin aids in regulating vascular tone, peristalsis, and platelet activation.

                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2014. | This topic last updated: Feb 24, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012; 50:911.
  2. Townsend E, Hawton K, Harriss L, et al. Substances used in deliberate self-poisoning 1985-1997: trends and associations with age, gender, repetition and suicide intent. Soc Psychiatry Psychiatr Epidemiol 2001; 36:228.
  3. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112.
  4. Prozac Package Insert 2005. Eli Lilly and Company (www.lilly.com).
  5. Graudins A, Dowsett RP, Liddle C. The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants. Emerg Med (Fremantle) 2002; 14:440.
  6. Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract 2000; 50:366.
  7. Stoner SC, Marken PA, Watson WA, et al. Antidepressant overdoses and resultant emergency department services: the impact of SSRIs. Psychopharmacol Bull 1997; 33:667.
  8. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310:221.
  9. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325:1332.
  10. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42:277.
  11. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 Suppl 15:42.
  12. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Geriatr Psychiatry Neurol 2003; 16:160.
  13. Movig KL, Leufkens HG, Lenderink AW, et al. Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol 2002; 53:363.
  14. Nahshoni E, Weizman A, Shefet D, Pik N. A case of hyponatremia associated with escitalopram. J Clin Psychiatry 2004; 65:1722.
  15. Ganetsky, M, Brush, E. Serotonin syndrome - what have we learned? Clin Ped Emerg Med 2005; 6:103.
  16. Spiller HA, Morse S, Muir C. Fluoxetine ingestion: a one year retrospective study. Vet Hum Toxicol 1990; 32:153.
  17. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46:59.
  18. Borys DJ, Setzer SC, Ling LJ, et al. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992; 10:115.
  19. Chiang, WK, Ford, MK, Wax, PM, et al. Prospective evaluation of fluoxetine ingestions (abstract). Vet Hum Toxicol 1990; 32:348.
  20. Phillips S, Brent J, Kulig K, et al. Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses. The Antidepressant Study Group. J Emerg Med 1997; 15:439.
  21. Moore JL, Rodriguez R. Toxicity of fluoxetine in overdose. Am J Psychiatry 1990; 147:1089.
  22. Compton R, Spiller HA, Bosse GM. Fatal fluoxetine ingestion with postmortem blood concentrations. Clin Toxicol (Phila) 2005; 43:277.
  23. Kincaid RL, McMullin MM, Crookham SB, Rieders F. Report of a fluoxetine fatality. J Anal Toxicol 1990; 14:327.
  24. Rohrig TP, Prouty RW. Fluoxetine overdose: a case report. J Anal Toxicol 1989; 13:305.
  25. Gross R, Dannon PN, Lepkifker E, et al. Generalized seizures caused by fluoxetine overdose. Am J Emerg Med 1998; 16:328.
  26. Braitberg G, Curry SC. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1995; 26:234.
  27. Riddle MA, Brown N, Dzubinski D, et al. Fluoxetine overdose in an adolescent. J Am Acad Child Adolesc Psychiatry 1989; 28:587.
  28. Graudins A, Vossler C, Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med 1997; 15:501.
  29. Cooper GL. The safety of fluoxetine--an update. Br J Psychiatry Suppl 1988; :77.
  30. Gardner SF, Rutherford WF, Munger MA, Panacek EA. Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann Emerg Med 1991; 20:194.
  31. Roberge RJ, Martin TG. Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med 1994; 23:586.
  32. McAnally LE, Threlkeld KR, Dreyling CA. Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 1992; 26:1090.
  33. Ahmed I, Dagincourt PG, Miller LG, Shader RI. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993; 38:62.
  34. Hofman, M, Liu, JK. Conduction abnormality and ventricular tachyarrhythmia associated with fluoxetine overdose (abstract). Vet Hum Toxicol 1994; 36:371.
  35. Appleby M, Mbewu A, Clarke B. Fluoxetine and ventricular torsade--is there a link? Int J Cardiol 1995; 49:178.
  36. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991; 6 Suppl 2:47.
  37. Caracci G. Unsuccessful suicide attempt by sertraline overdose. Am J Psychiatry 1994; 151:147.
  38. Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses. Am J Emerg Med 1996; 14:456.
  39. Lau GT, Horowitz BZ. Sertraline overdose. Acad Emerg Med 1996; 3:132.
  40. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 Suppl:61.
  41. Myers, LB, Dean, BS, Krenelok, EP. Paroxetine (Paxil): overdose assessment of a new selective serotonin reuptake inhibitor (abstract). Vet Hum Toxicol 1994; 36:370.
  42. Tonks A. Withdrawal from paroxetine can be severe, warns FDA. BMJ 2002; 324:260.
  43. Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993; 21:197.
  44. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 54:146.
  45. Tan JY, Levin GM. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999; 19:675.
  46. Personne M, Sjöberg G, Persson H. Citalopram overdose--review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35:237.
  47. Personne M, Persson H, Sjöberg E. Citalopram toxicity. Lancet 1997; 350:518.
  48. Bin Salih S, Al Qahtani M, Al Anazi T, et al. Metabolic acidosis and generalized seizures secondary to citalopram overdose: a case report. J Clin Pharm Ther 2010; 35:479.
  49. Celexa Package Insert (2005). Forest Pharmaceuticals, http://www.frx.com/pi/celexa_pi.pdf (Accessed March 23, 2006).
  50. Rasmussen SL, Overø KF, Tanghøj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19:407.
  51. Grundemar L, Wohlfart B, Lagerstedt C, et al. Symptoms and signs of severe citalopram overdose. Lancet 1997; 349:1602.
  52. Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42:67.
  53. Catalano G, Catalano MC, Epstein MA, Tsambiras PE. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol 2001; 24:158.
  54. Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med 2003; 25:163.
  55. Meuleman C, Jourdain P, Bellorini M, et al. [Citalopram and Torsades de Pointes. A case report]. Arch Mal Coeur Vaiss 2001; 94:1021.
  56. Tarabar, AF, Hoffman, RS, Nelson, LS. Citalopram overdose: late presentation of Torsades de Pointes (TdP) with cardiac arrest (abstract #86). J Toxicol Clin Toxicol 2003; 41:676.
  57. Fayssoil A, Issi J, Guerbaa M, et al. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris) 2011; 60:165.
  58. de Gregorio C, Morabito G, Cerrito M, et al. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol 2011; 148:226.
  59. Blaschke D, Parwani AS, Huemer M, et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 2007; 40:294.
  60. Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 2008; 131:e33.
  61. Snider RD. Case report: left bundle branch block--a rare complication of citalopram overdose. J S C Med Assoc 2001; 97:380.
  62. Rothenhäusler HB, Hoberl C, Ehrentrout S, et al. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 2000; 33:150.
  63. Cuenca PJ, Holt KR, Hoefle JD. Seizure secondary to citalopram overdose. J Emerg Med 2004; 26:177.
  64. Liotier J, Coudoré F. Drug monitoring of a case of citalopram overdosage. Drug Chem Toxicol 2011; 34:420.
  65. Oström M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet 1996; 348:339.
  66. Escitalopram (lexapro) for depression. Med Lett Drugs Ther 2002; 44:83.
  67. van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009; 54:404.
  68. Barnett, AK, Brush, DE, Schroeder, W. The pharmacology and toxicology of escitalopram. Int J Med Toxicol 2003; 6:14.
  69. Lexapro Package Insert (2005), Forest Pharmaceuticals, http://www.frx.com/pi/lexapro_pi.pdf (Accessed March 23, 2006).
  70. Yilmaz Z, Ceschi A, Rauber-Lüthy C, et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila) 2010; 48:207.
  71. Abstracts of the North American Congress of Clinical Toxicology Annual Meeting. September 4-9, 2003. Chicago, Illinois, USA. J Toxicol Clin Toxicol 2003; 41:641.
  72. Ginsburg, BY, Wiener, SW, Henderson, KJ, et al. QTc interval prolongation associated with escitalopram overdose (abstract #174). J Toxicol Clin Toxicol 2005; 43:502.
  73. Scharko AM, Schumacher J. Prolonged QTc interval in a 14-year-old girl with escitalopram overdose. J Child Adolesc Psychopharmacol 2008; 18:297.
  74. Yuksel FV, Tuzer V, Goka E. Escitalopram intoxication. Eur Psychiatry 2005; 20:82.
  75. Olsen, DG, Dart, RC, Robinett, M. Severe serotonin syndrome from escitalopram overdose. J Toxicol Clin Toxicol 2004; 42:744.
  76. Huska MT, Catalano G, Catalano MC. Serotonin syndrome associated with the use of escitalopram. CNS Spectr 2007; 12:270.
  77. Lindgren, KN, et al. Escitalopram, a review of adverse effects in overdose reported to select regional poison centers (abstract #41). J Toxicol Clin Toxicol 2003; 41:658.
  78. Chyka PA, Seger D, Krenzelok EP, et al. Position paper: Single-dose activated charcoal. Clin Toxicol 2005; 43:61.
  79. Isbister GK, Friberg LE, Stokes B, et al. Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med 2007; 50:593.
  80. van Gorp F, Duffull S, Hackett LP, Isbister GK. Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Br J Clin Pharmacol 2012; 73:402.
  81. Keren A, Tzivoni D. Torsades de pointes: prevention and therapy. Cardiovasc Drugs Ther 1991; 5:509.
  82. Baker SD, Morgan DL. Fluoxetine exposures: are they safe for children? Am J Emerg Med 2004; 22:211.
  83. Myers, LB, Dean, BS, Krenzelok, EP. Sertraline (Zoloft): a pediatric overdose approach (abstract). Vet Human Toxicol 1994; 36:361.
  84. Myers LB, Krenzelok EP. Paroxetine (Paxil) overdose: a pediatric focus. Vet Hum Toxicol 1997; 39:86.
  85. Fraser J, South M. Life-threatening fluvoxamine overdose in a 4-year-old child. Intensive Care Med 1999; 25:548.
  86. Horowitz BZ, Mullins ME. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatr Emerg Care 1999; 15:325.
  87. Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994; 23:1371.
  88. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med 1999; 33:457.
  89. Mosby. Mosby's Drug Consult: A Comprehensive Reference for Brand and Generic Prescription Drugs, Mosby, Philadelphia 2002.
  90. Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr (Phila) 2001; 40:681.
  91. Isbister GK, Dawson A, Whyte IM, et al. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001; 85:F147.